Arrowhead Pharmaceuticals Inc. (ARWR) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $59.57 (-0.55% 1D, market cap $8.46B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, ARWR ranks #181 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ARWR carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 11.1%. By comparison, CYTK (Cytokinetics Incorporated) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $8.76B) and CORT (Corcept Therapeutics Incorporated) posts a C grade (63/100 RQD, P/E 93.2x, ROIC 4.8%, cap $8.77B). Among the 5-stock peer group, TGTX leads on earnings multiple (19.9x) while TGTX leads on capital efficiency (12.0% ROIC).
Per ARWR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0000879407), Arrowhead Pharmaceuticals Inc. generated $829.4M in revenue (+23258.2% YoY), -$1.6M in net income, and $156.9M in free cash flow against $1.60B in total assets and $375.4M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 18.9% FCF Margin ($156.9M FCF) & 52% Gross Margin
Altman Z-Score 6.60 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9
Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)
Even with a 58/100 (D+) score, ARWR faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
Dilution & Margin Drag: Disciplined Float (-0.32% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($68.15) or 200D SMA ($71.66) invalidates the momentum regime and cuts Target Base ($59.57) toward Bear Floor ($46.46).
Arrowhead Pharmaceuticals Inc. (ARWR) slipped -0.55% to $59.57, trading at 39% of its 52-week range ($37.06 – $95.49). Stretched risk/reward at current multiples (11% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Arrowhead Pharmaceuticals Inc. (ARWR) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Arrowhead Pharmaceuticals Inc. (ARWR) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Arrowhead Pharmaceuticals Inc. (ARWR) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Arrowhead Pharmaceuticals Inc. (ARWR) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Arrowhead Pharmaceuticals Inc. (ARWR) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Arrowhead Pharmaceuticals Inc. (ARWR) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Arrowhead Pharmaceuticals Inc. (ARWR) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Arrowhead Pharmaceuticals Inc. (ARWR) market action, institutional positioning, and fundamental catalysts.
PASADENA, Calif., November 02, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it will present important data at this week’s American Heart Association Scientific Sessions in Chicago.
– Detailed Results from the Phase 1/2a Study of ARO-DIMER-PA, the First Dual-Functional Investigational RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia, Will Be Presented at Late-breaking Featured Science
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +23258.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ARWR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ARWR. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Arrowhead Pharmaceuticals Inc. (ARWR) ranks #181 by composite RQD confidence (58/100, grade D+) and #124 by equity capitalization ($8.46B). Within this direct 5-issuer industry benchmark cohort, TGTX leads on earnings valuation at 19.9x trailing P/E, while TGTX leads on capital efficiency and profitability with 12.0% ROIC and 83.7% gross margin. CORT currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with ARWR at 58/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ARWR
ACTIVE
Arrowhead Pharmaceuticals Inc. | D+ | 58/100 | — | — | 11.1% | -0.55% | $8.46B | Benchmark Subject |
| CYTK Cytokinetics Incorporated | E | 28/100 | — | — | -35.0% | -1.52% | $8.76B | /cytk-vs-arwr → |
| CORT Corcept Therapeutics Incorporated | C | 63/100 | 93.2x | 96.0% | 4.8% | -0.81% | $8.77B | /cort-vs-arwr → |
| PRAX Praxis Precision Medicines Inc. | D | 48/100 | — | — | -35.0% | -4.18% | $7.98B | /prax-vs-arwr → |
| TGTX TG Therapeutics Inc. | C | 63/100 | 19.9x | 83.7% | 12.0% | -2.01% | $9.36B | /tgtx-vs-arwr → |
In its most recent audited fiscal period (FY2025, filed 2025-09-30), Arrowhead Pharmaceuticals Inc. (ARWR) reported GAAP revenue of $829.4M (+23258.2% vs. FY2024 revenue of $3.6M , and +244.5% cumulative change since FY2023) , GAAP net income of -$1.6M, operating cash flow of $179.6M, and free cash flow of $156.9M (+126.0% YoY). On the balance sheet, ARWR closed FY2025 with $1.60B in total assets against $375.4M in total debt (Altman Z-Score: 6.60, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-09-30 | $829.4M | -$1.6M | $179.6M | $156.9M | $1.60B | $375.4M |
| FY2024 (FY) | 2024-09-30 | $3.6M | -$599.5M | -$462.9M | -$604.3M | $1.01B | $237.2M |
| FY2023 (FY) | 2023-09-30 | $240.7M | -$205.3M | -$153.9M | -$164.7M | $4.70B | $1.10B |
As of 2026-11-03, Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $59.57 (-0.55% 1D, market cap $8.46B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, ARWR ranks #181 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ARWR carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 11.1%. By comparison, CYTK (Cytokinetics Incorporated) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $8.76B) and CORT (Corcept Therapeutics Incorporated) posts a C grade (63/100 RQD, P/E 93.2x, ROIC 4.8%, cap $8.77B). Among the 5-stock peer group, TGTX leads on earnings multiple (19.9x) while TGTX leads on capital efficiency (12.0% ROIC).
Per ARWR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0000879407), Arrowhead Pharmaceuticals Inc. generated $829.4M in revenue (+23258.2% YoY), -$1.6M in net income, and $156.9M in free cash flow against $1.60B in total assets and $375.4M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
ARWR last traded at $59.57 (-0.55% on volume of 1,314,070 shares), positioning the stock -12.59% below its 50-day simple moving average ($68.15) and -16.87% below its 200-day simple moving average ($71.66). Across its 52-week range of $37.06 to $95.49, ARWR sits at the 38.5% percentile with a 14-day RSI of 41.3 (NEUTRAL RANGE) and an implied next-earnings move of ±7.4% ($55.16 to $63.98).
Arrowhead Pharmaceuticals Inc. (ARWR) earns a live Roarable RQD composite score of 58/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $59.57 (-0.55% 1D, market capitalization $8.46B).
Arrowhead Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Pharmaceutical Preparations. The company reported revenue of $829.4M for FY 2025 after $3.6M for FY 2024, indicating a sharp change in its revenue base over the reported periods.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-09-30), Arrowhead Pharmaceuticals Inc. (ARWR) reported $829.4M in annual revenue (up from $3.6M in FY2024, +23258.2% YoY) and -$1.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($240.7M revenue, -$205.3M net income) through FY2025, ARWR scaled operating cash flow to $179.6M and free cash flow to $156.9M, backed by $1.60B in total assets against $375.4M in total debt.
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), ARWR carries a macro regime beta of 0.96 and gross margin of —.
Real-time company headlines, analyst actions, and sector developments for Arrowhead Pharmaceuticals Inc. (ARWR) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Arrowhead Pharmaceuticals Inc. (ARWR) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Arrowhead Pharmaceuticals Inc. (ARWR) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Arrowhead Pharmaceuticals Inc. (ARWR) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Arrowhead Pharmaceuticals Inc. (ARWR) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Arrowhead Pharmaceuticals Inc. (ARWR) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Arrowhead Pharmaceuticals Inc. (ARWR) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Arrowhead Pharmaceuticals Inc. (ARWR) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Arrowhead Pharmaceuticals Inc. (ARWR) market action, institutional positioning, and fundamental catalysts.
Don't sleep on ARWR's setup in Health Care. Operating income swung to $98.3M in FY 2025 while debt fell from $1.10B to $375.4M, and the forensic balance sheet scores 16 of 20.. Beta of 0.96 means it moves fast when momentum turns, and the 5-pillar RQD gauge (58/100) backs up the fundamental quality.
Both sides have a point here — ARWR's 16/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
Here is the bear case nobody on the bull side wants to address on ARWR: Net income remained negative at -$1.6M in FY 2025, the EV/EBITDA of 73.8 is high, and institutional flow scores only 5 of 20.. At 18.0x forward P/E, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: